RxDoctor Payments Data

Jonathan Blossom, MD

Internal Medicine · Tupelo, MSNPI 1407235617

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $9,073 of the $10,994 with a category attached, or 82.5%. 33 manufacturers reported payments, led by Medtronic at 29.2% of the total. Reporting peaked in 2022 at $3,643 and has fallen 58.2% since, to $1,522 in 2025. Among internal medicine clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,994in general payments, 2019–2025

Across 305 payments — averaging $36.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Abiomed$1K
  • Inari Medical, Inc.$801
  • Penumbra, Inc.$689
  • Pfizer$673
  • AstraZeneca$428
  • plus $4K from 27 others
$71,720in research payments, 2019–2025

Across 6 payments — averaging $11,953 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cathworks, Inc.$72K

What the payments were for

  • Travel & lodging$1,74416%
  • Food & beverage$9,07383%
  • Education$1772%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,994 in reported general payments places this provider in the 95th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$342,898
Medicare patients
1,287
Services billed
8,127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan107$93,052
JardianceEmpagliflozin98$67,670
EliquisApixaban58$50,418
FarxigaDapagliflozin Propanediol48$44,023
Repatha SureclickEvolocumab35$24,287
BrilintaTicagrelor36$19,135
Praluent PenAlirocumab12$7,166
Ranolazine ErRanolazine44$4,049
Ezetimibe93$2,005
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide18$1,993
Rosuvastatin Calcium282$1,986
Metoprolol Succinate250$1,926
Isosorbide Mononitrate ErIsosorbide Mononitrate205$1,879
Nitroglycerin61$1,768
Atorvastatin Calcium233$1,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$317$93,052107 claims
Boehringer IngelheimJardiance$341$67,67098 claims
AstraZenecaFarxiga, Brilinta$428$63,15884 claims
PfizerEliquis$673$50,41858 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →